Gonodrotropins - because ganirelix can suppress the secretion of pitutiary gonodotropin , dose
adjustments of exogenous gonodrotropins may be necessary when used during the controlled
ovarian stimulation

Infertility

Adverse reactions-

Abdominal pain  gynaecological    4%    death fetal 3%   Headache 3%   

Ovarian hyperstimulation syndrome 2%

Vaginal bleeding   1%    Injection site reaction 1%  Abdominal pain 1%

Hypersensitivity to any of its components

Special Precautions-

Latex allergy-  the packing of this product contains natural rubber latex which may cause
allergic reaction

Hypersensitivity reactions- caution is  advised in patients with hypersensitivity to GnRH
Carefully monitor these patients after the first injection
Anaphylactic reactions of ganirelix have not been reported

Pregnancy- safe use of ganerelix during pregnancy has not been established

Lactation-  not known whether this drug is excreted in breast milk .
Ganerelix should not be used by breast-feeding women.

Indication-
Infertility

Dosage-

After initiating follicle stimulating hormone FSH therapy, on day 2 or 3 of the cycle ganirelix 250mcg
may be adminstered subcutaneously once daily during the early -to-mild follicular phase

1. Prior to therapy with ganerelix, inform patients of the duration of the treatment and monitoring
    procedures that will be required.

2. Discuss the risk of possible adverse reactions.

3. Do not prescribe ganerelix if the patient is pregnant

Pregnancy-
Safe use of ganerelix during pregnancy has not been established

Lactation- 
Not known whether this drug is excreted in breast milk .
Ganerelix should not be used by breast-feeding women.